èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã PDS ãã€ãªãã¯ãããžãŒ ã³ãŒãã¬ãŒã·ã§ã³ã¯ã倿©èœããå
ç«çæ³ã®éçºã«æ³šåããŠããŸããäž»å補ååè£ã¯ PDS0101 (HPV16) ã§ãåçºæ§/転移æ§é é žéšãããããããããŒããŠã€ã«ã¹é¢é£æªæ§è
«çãåå®®é žããã®ç¬¬äžéžææ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšãè¡ãããŠããŸããå瀟ã¯ãŸããåç«è
ºãããšä¹³ããã®æ²»çãç®çãšãã T 现èå容äœã¬ã³ã代æ¿èªã¿æ ã¿ã³ãã¯è³ª (TARP) ã® PDS0102ãåµå·£ããã倧è
žãããèºãããä¹³ããã察象ãšãã PDS0103 (MUC-1)ãããã³é»è²è
«ã®æ²»çãç®çãšããããã·ããŒãŒé¢é£ã¿ã³ãã¯è³ª 2 ãå«ã PDS0104 ãªã©ãåèšåºè©Šé𿮵éã«ããããŸããŸãªè£œååè£ãéçºããŠããŸããããã«ãçµæ žæ²»çè¬ã® PDS0201ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³åè£ã® PDS0202 ãéçºäžã§ãããŸããCOVID-19ã®äºé²çšã¯ã¯ãã³PDS0203ãéçºããŠããŸããå瀟ã¯ãåœç«è¡çç ç©¶æãMerck Eprova AGãç±³åœä¿å¥çŠç¥çãMSD International GmbHãšã©ã€ã»ã³ã¹å¥çŽããã³ååå¥çŽãçµãã§ããŸããPDS Biotechnology Corporationã¯2005幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ãããŒã©ã ããŒã¯ã«æ ç¹ã眮ããŠããŸãã